Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
29.48
+1.31 (4.65%)
Jul 21, 2026, 4:00 PM EDT - Market closed
Arcus Biosciences Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Arcus Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $36.83. The average 1-year stock price forecast is 24.93% higher than the current stock price, while the lowest is $22 (-25.37%) and the highest is $47 (+59.43%).
Price Target: $36.83 (+24.93%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Arcus Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 9 | 10 | 10 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $32 → $45 | Buy | Reiterates | $32 → $45 | +52.65% | Jul 20, 2026 |
Unknown Analyst Mizuho Securities No rating | Mizuho Securities | Buy Maintains $47 | Buy | Maintains | $47 | +59.43% | Jun 10, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 4, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Initiates $46 | Buy | Initiates | $46 | +56.04% | Jun 4, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $20 → $22 | Hold | Maintains | $20 → $22 | -25.37% | May 11, 2026 |
Financial Forecast
Revenue This Year
85.06M
from 247.00M
Decreased by -65.56%
Revenue Next Year
93.06M
from 85.06M
Increased by 9.40%
EPS This Year
-3.48
from -3.29
EPS Next Year
-3.10
from -3.48
EPS and Forward PE are based on non-GAAP adjusted numbers.